Haemoglobin A 1c cut-off point to identify a high risk group of future diabetes: Results from the Omiya MA Cohort Study

Diabetic Medicine

Volumn 29, Issue 7, 2012, Pages 905-910

  Kato, M ^a   Noda, M ^b   Suga, H ^c   Nakamura, T ^c   Matsumoto, M ^c   Kanazawa, Y ^d  

^a Japan Foundation for the Promotion of International Medical Research Cooperation   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c Omiya Medical Association   (Japan)

^d Japan Diabetes Foundation   (Japan)

Author keywords

Diabetes; Epidemiology; Fasting blood glucose; HbA 1c; Impaired fasting glucose

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FASTING PLASMA GLUCOSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; RETROSPECTIVE STUDY; ALGORITHM; ASIAN; BLOOD; DIET RESTRICTION; JAPAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR;

ADULT; AGED; ALGORITHMS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE;

EID: 84862705297     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03572.x     Document Type: Article

References (21)

1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010; 33: S62-S69.
2. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212-228.
3. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Available at http:// last accessed 24 February 2011.
4. Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application to breast cancer data. Biometrics 1978; 34: 57-67.
5. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
6. Kadowaki T, Haneda M, Tominaga M, Yamada N, Iwamoto Y, Tajima N et al. Report of the Japan Diabetes Society's Committee on the Diagnostic Criteria for Diabetes Mellitus and Glucose Metabolism Disorder - a new category of fasting plasma glucose values: 'high-normal'. J Japan Diab Soc 2008; 51: 281-283.
7. Kato M, Noda M, Suga H, Matsumoto M, Kanazawa Y. Fasting plasma glucose and incidence of diabetes - implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA Cohort Study. J Atheroscler Thromb 2009; 16: 857-861.
8. Noda M, Kato M, Takahashi Y, Matsushita Y, Mizoue T, Inoue M et al. Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study - suggestion for the threshold for impaired fasting glucose among Japanese. Endocr J 2010; 57: 629-637.
9. Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract 2000; 50: 225-230.
10. Mohan V, Vijayachandrika V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010; 33: 515-519.
11. Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 2010; 33: 1665-1673.
12. Cederberg H, Saukkonen T, Laakso M, Jokelainen J, Harkonen P, Timonen M et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study. Diabetes Care 2010; 33: 2077-2083.
13. Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010; 33: 2104-2109.
14. Shimazaki T, Kadowaki T, Ohyama Y, Ohe K, Kubota K. Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl Res 2007; 149: 196-204.
15. Inoue K, Matsumoto M, Kobayashi Y. The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. Diabetes Res Clin Pract 2007; 77: 451-458.
16. Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 2009; 32: 644-646.
17. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
18. Rohlfing C, Wiedmeyer HM, Little R, Grotz VL, Tennill A, England J et al. Biological variation of glycohemoglobin. Clin Chem 2002; 48: 1116-1118.
19. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-472.
20. Schnedl WJ, Liebminger A, Roller RE, Lipp RW, Krejs GJ. Hemoglobin variants and determination of glycated hemoglobin (HbA1c). Diabetes Metab Res Rev 2001; 17: 94-98.
21. Lahousen T, Hegenbarth K, Ille R, Lipp RW, Krause R, Little RR et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 2004; 10: 2284-2286.